Well actually it happened on June 14 at 14 pm ... San Luis Gonzaga rested his feet on ground obligadense.
But you had to see it.
Monday, July 13, 2009
What Do Colored Plastic Bracelets Mean?
already happened ... but ... impossible not to show
But you had to see it.
But you had to see it.
Tuesday, July 7, 2009
Askthebuilder.com Template
Participating in a clinical trial: a moral obligation?
A provocative article
So far, cooperation in the tests necessary to develop new treatments is presented as voluntary. It is reprehensible that a patient refuses to be tested in a drug organization whose ultimate effect is unknown. But the provocative thesis defending the authors of an article published in The Journal of the American Medical Association "(" JAMA ") is that this type of work are key to scientific progress and as the results benefit the entire society should be considered as a public good, like "national security or clean air."
Thus, among the social benefits that have been reported scientific knowledge in the last century quote the eradication of polio, the development of penicillin or the incorporation of new surgical techniques, such as lumpectomy, the minimally invasive removal of breast tumors that is as effective as mastectomy.
To carry out these studies are indispensable to the researchers, institutions and agencies that promote them. Also adequate funding. But equally important are the millions of people, healthy and sick, who enter the work involved in showing both the effectiveness and the lack of usefulness of interventions. "The absence of participants more difficult than shortage of funds the development of clinical trials, "the authors remind, experts of the Department of Bioethics at the National Institutes of Health U.S..
is the reason for appealing to "moral obligation" for the citizens to support this system to generate knowledge through their involvement in the tests, provided that "the cost and risks" to intervene "not exceed the benefits "research. "If the risk is significant, the obligation is weakened" he said.
However, this incentive to comply with the duty, you get to match in that article with the call-up of civil society Time of War, has its limitations. While noting that a "duty" to participate in such studies and, to refuse, it "should cite a good reason," that "does not mean that the patient should be legally ordered to cooperate" or to be reduced informed consent requirements and, also, eliminate the right to withdraw from the research.
"We call for a cultural change and moral, not legal," the authors nuance, seeking health professionals' greater willingness to actively recruit patients for clinical trials important. "
"It is a highly theoretical approach," Albert believes Jovell, president of the English Patient Forum, an umbrella that represents more than a hundred national associations of patients. However, it recognizes the need for some "education" on what is a clinical trial, because culture is about "minority." The patient "needs to know what it is and why it is important to participate," he adds.
However, Jovell highlights the "generosity" of patients who collaborate with this research: "It is true that they are more guarded and receive better care, but are exposed to uncertainty about the side effects of drugs and diagnostic tests more usual. "
Jesus San Miguel, chief of Service and Professor of Clinical Hematology, Hospital Universitario de Salamanca, shares the philosophy of a more "commitment" of doctors and patients to clinical trials. "They may be approved drugs which then benefit others who have not contributed to them," he says. Agrees on the need for a change of culture "in which insist on the great benefit of this activity, that has nothing to do with 'guinea pigs' because it is a rigorous quality work offered by the better care for patients. " San Miguel
regrets the insufficient involvement of some doctors in recruiting ill. "Increased awareness is needed to refer patients to trials. You should see the fact of promoting this activity as a key in their practice, and it is essential to scientific progress. "
however, recognized that Spain is facing, in addition, another problem: the enormous bureaucracy involved in conducting clinical trials in several autonomy at a time. The last one by the English Myeloma Group required to make about three million copies for the various committees that assessed the same project.
A provocative article
considered a civic duty to collaborate on studies that promote the advancement of science and argues for a cultural change that encourages involvement in this activity.
"Science needs you. It's your turn. Collaborate." It's the kind of message that should be spread among the public to foster a cultural shift in favor of actively participating in biomedical research. Because scientific progress needs patients. An example: if the proportion of cancer patients participating in clinical trials current increases from 5% to 10%, the duration of these studies could be reduced from four a current year.
So far, cooperation in the tests necessary to develop new treatments is presented as voluntary. It is reprehensible that a patient refuses to be tested in a drug organization whose ultimate effect is unknown. But the provocative thesis defending the authors of an article published in The Journal of the American Medical Association "(" JAMA ") is that this type of work are key to scientific progress and as the results benefit the entire society should be considered as a public good, like "national security or clean air."
Thus, among the social benefits that have been reported scientific knowledge in the last century quote the eradication of polio, the development of penicillin or the incorporation of new surgical techniques, such as lumpectomy, the minimally invasive removal of breast tumors that is as effective as mastectomy. To carry out these studies are indispensable to the researchers, institutions and agencies that promote them. Also adequate funding. But equally important are the millions of people, healthy and sick, who enter the work involved in showing both the effectiveness and the lack of usefulness of interventions. "The absence of participants more difficult than shortage of funds the development of clinical trials, "the authors remind, experts of the Department of Bioethics at the National Institutes of Health U.S..
is the reason for appealing to "moral obligation" for the citizens to support this system to generate knowledge through their involvement in the tests, provided that "the cost and risks" to intervene "not exceed the benefits "research. "If the risk is significant, the obligation is weakened" he said.
However, this incentive to comply with the duty, you get to match in that article with the call-up of civil society Time of War, has its limitations. While noting that a "duty" to participate in such studies and, to refuse, it "should cite a good reason," that "does not mean that the patient should be legally ordered to cooperate" or to be reduced informed consent requirements and, also, eliminate the right to withdraw from the research.
"We call for a cultural change and moral, not legal," the authors nuance, seeking health professionals' greater willingness to actively recruit patients for clinical trials important. " "It is a highly theoretical approach," Albert believes Jovell, president of the English Patient Forum, an umbrella that represents more than a hundred national associations of patients. However, it recognizes the need for some "education" on what is a clinical trial, because culture is about "minority." The patient "needs to know what it is and why it is important to participate," he adds.
However, Jovell highlights the "generosity" of patients who collaborate with this research: "It is true that they are more guarded and receive better care, but are exposed to uncertainty about the side effects of drugs and diagnostic tests more usual. "
Jesus San Miguel, chief of Service and Professor of Clinical Hematology, Hospital Universitario de Salamanca, shares the philosophy of a more "commitment" of doctors and patients to clinical trials. "They may be approved drugs which then benefit others who have not contributed to them," he says. Agrees on the need for a change of culture "in which insist on the great benefit of this activity, that has nothing to do with 'guinea pigs' because it is a rigorous quality work offered by the better care for patients. " San Miguel
regrets the insufficient involvement of some doctors in recruiting ill. "Increased awareness is needed to refer patients to trials. You should see the fact of promoting this activity as a key in their practice, and it is essential to scientific progress. "
however, recognized that Spain is facing, in addition, another problem: the enormous bureaucracy involved in conducting clinical trials in several autonomy at a time. The last one by the English Myeloma Group required to make about three million copies for the various committees that assessed the same project.
Subscribe to:
Posts (Atom)